Antigen-Directed, Cancer-Specific Targeting Agent for PET-Based Imaging Shows Promise

A cancer imaging study, an antigen-directed, cancer-specific targeting agent demonstrated superior performance over the industry standard, ¹⁸F-flurodeoxyglucose (FDG), in positron emission tomography (PET) imaging of colorectal cancer.

In the study, Enlyton's (Columbus, OH, USA) targeting agent increasingly localized in tumor, while ¹⁸F-FDG did not. ¹⁸F-FDG also exhibited the tendency to localize in normal tissues. Dr. Edward Martin, Jr., Enlyton CSO and professor of surgery at the Ohio State University (Columbus, USA), said, "We are excited with the results of the study and the potential it offers for successful use of our cancer-specific targeting agent in clinical trials for preoperative, intraoperative, and postoperative PET-based imaging of colorectal cancer.”

The study was conducted by researchers from Enlyton, Ltd., the Ohio State University, and the University of Michigan (Ann Arbor, USA) and was published in the August 6, 2010, issue of the World Journal of Surgical Oncology.

Related Links:
Enlyton
Ohio State University
University of Michigan